ABCELLERA BIOLOGICS Net Assets
ABCELLERA BIOLOGICS net assets. Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has net assets worth €896.02 Million EUR (≈ $1.05 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.31 Billion ≈ $1.53 Billion USD) and total liabilities (€411.56 Million ≈ $481.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 8QQ year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €896.02 Million |
| % of Total Assets | 68.53% |
| Annual Growth Rate | -1.47% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.16 |
Net Assets of ABCELLERA BIOLOGICS (2021–2025)
Net assets of ABCELLERA BIOLOGICS from 2021 to 2025. This chart illustrates how ABCELLERA BIOLOGICS's net assets have evolved over time, based on quarterly financial data. See 8QQ equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual net assets of ABCELLERA BIOLOGICS from 2021 to 2025. For live market cap and overall valuation, see ABCELLERA BIOLOGICS (8QQ) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €966.90 Million ≈ $1.13 Billion |
-8.44% |
| 2024-12-31 | €1.06 Billion ≈ $1.23 Billion |
-8.35% |
| 2023-12-31 | €1.15 Billion ≈ $1.35 Billion |
-6.56% |
| 2022-12-31 | €1.23 Billion ≈ $1.44 Billion |
+20.23% |
| 2021-12-31 | €1.03 Billion ≈ $1.20 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ABCELLERA BIOLOGICS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ABCELLERA BIOLOGICS Net Assets Breakdown (December 2025)
ABCELLERA BIOLOGICS net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €996.39 Million | 103.05% |
| Total Equity | €966.90 Million | 100.00% |
ABCELLERA BIOLOGICS Competitors by Market Cap
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Communications Construction Company Limited
F:CYY
|
$3.15 Billion |
|
Breville Group Ltd
AU:BRG
|
$3.15 Billion |
|
Wynn Macau Limited
F:8WY
|
$3.15 Billion |
|
Zhende Medical Co Ltd
SHG:603301
|
$3.15 Billion |
|
Nelnet Inc
NYSE:NNI
|
$3.15 Billion |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
$3.15 Billion |
|
Hisense Kelon Electrical Holdings Co Ltd
SHE:000921
|
$3.15 Billion |
|
Société Anonyme des Bains de Mer et du Cercle des Étrangers à Monaco
F:RJ8
|
$3.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABCELLERA BIOLOGICS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,056,084,000 to 966,904,000, a change of -89,180,000 (-8.4%).
- Net loss of 146,412,000 reduced equity.
- Other factors increased equity by 57,232,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-146.41 Million | -15.14% |
| Other Changes | €57.23 Million | +5.92% |
| Total Change | €- | -8.44% |
Book Value vs Market Value Analysis
This analysis compares ABCELLERA BIOLOGICS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.93x to 3.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.62 | €10.60 | x |
| 2022-12-31 | €4.30 | €10.60 | x |
| 2023-12-31 | €3.96 | €10.60 | x |
| 2024-12-31 | €3.57 | €10.60 | x |
| 2025-12-31 | €3.22 | €10.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABCELLERA BIOLOGICS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -194.88%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.40x
- Recent ROE (-15.14%) is below the historical average (-3.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 14.96% | 40.90% | 0.28x | 1.29x | €50.89 Million |
| 2022 | 12.85% | 32.66% | 0.32x | 1.25x | €35.19 Million |
| 2023 | -12.70% | -385.00% | 0.03x | 1.29x | €-261.63 Million |
| 2024 | -15.42% | -564.83% | 0.02x | 1.29x | €-268.47 Million |
| 2025 | -15.14% | -194.88% | 0.06x | 1.40x | €-243.10 Million |
Industry Comparison
This section compares ABCELLERA BIOLOGICS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABCELLERA BIOLOGICS (8QQ) | €896.02 Million | 14.96% | 0.46x | $3.15 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more